Srinivas Ramishetti
Overview
Explore the profile of Srinivas Ramishetti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
1080
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tarab-Ravski D, Stotsky-Oterin L, Elisha A, Kundoor G, Ramishetti S, Hazan-Halevy I, et al.
J Control Release
. 2024 Oct;
376:286-302.
PMID: 39401676
Genetic medicines hold vast therapeutic potential, offering the ability to silence or induce gene expression, knock out genes, and even edit DNA fragments. Applying these therapeutic modalities to leukocytes offers...
2.
Granot-Matok Y, Ezra A, Ramishetti S, Sharma P, Somu Naidu G, Benhar I, et al.
Theranostics
. 2023 Jul;
13(11):3497-3508.
PMID: 37441597
: Cancer therapy have evolved remarkably over the past decade, providing new strategies to inhibit cancer cell growth using immune modulation, with or without gene therapy. Specifically, suicide gene therapies...
3.
Somu Naidu G, Yong S, Ramishetti S, Rampado R, Sharma P, Ezra A, et al.
Adv Sci (Weinh)
. 2023 Apr;
10(19):e2301929.
PMID: 37092557
Ionizable lipid-based nanoparticles (LNPs) are the most advanced non-viral drug delivery systems for RNA therapeutics and vaccines. However, cell type-specific, extrahepatic mRNA delivery is still a major hurdle, hampering the...
4.
Chatterjee S, Somu Naidu G, Hazan-Halevy I, Grobe H, Ezra A, Sharma P, et al.
Sci Adv
. 2023 Apr;
9(14):eade4800.
PMID: 37018392
The potential of microtubule-associated protein targets for cancer therapeutics remains largely unexplored due to the lack of target-specific agents. Here, we explored the therapeutic potential of targeting cytoskeleton-associated protein 5...
5.
Poley M, Mora-Raimundo P, Shammai Y, Kaduri M, Koren L, Adir O, et al.
ACS Nano
. 2022 Mar;
16(4):5246-5257.
PMID: 35293714
Throughout the female menstrual cycle, physiological changes occur that affect the biodistribution of nanoparticles within the reproductive system. We demonstrate a 2-fold increase in nanoparticle accumulation in murine ovaries and...
6.
Yong S, Ramishetti S, Goldsmith M, Diesendruck Y, Hazan-Halevy I, Chatterjee S, et al.
Adv Mater
. 2022 Jan;
34(13):e2106350.
PMID: 35044699
Chemo-immunotherapy is a combination of "standard-of-care" chemotherapy with immunotherapy and it is considered the most advanced therapeutic modality for various types of cancers. However, many cancer patients still poorly respond...
7.
Kampel L, Goldsmith M, Ramishetti S, Veiga N, Rosenblum D, Gutkin A, et al.
J Control Release
. 2021 Jul;
337:378-389.
PMID: 34303750
Currently there are no specific therapies addressing the distinctive biology of human papillomavirus (HPV)-induced cancer approved for clinical use. Short interfering RNA (siRNA) has much potential for therapeutic manipulation of...
8.
Dammes N, Goldsmith M, Ramishetti S, Dearling J, Veiga N, Packard A, et al.
Nat Nanotechnol
. 2021 Jun;
16(9):1030-1038.
PMID: 34140675
The successful in vivo implementation of gene expression modulation strategies relies on effective, non-immunogenic delivery vehicles. Lipid nanoparticles are one of the most advanced non-viral clinically approved nucleic-acid delivery systems....
9.
Elia U, Rotem S, Bar-Haim E, Ramishetti S, Somu Naidu G, Gur D, et al.
Nano Lett
. 2021 May;
21(11):4774-4779.
PMID: 34032435
The COVID-19 pandemic led to development of mRNA vaccines, which became a leading anti-SARS-CoV-2 immunization platform. Preclinical studies are limited to infection-prone animals such as hamsters and monkeys in which...
10.
Singh M, Ramishetti S, Landesman-Milo D, Goldsmith M, Chatterjee S, Palakuri R, et al.
Small
. 2021 Apr;
17(19):e2100287.
PMID: 33825318
Ovarian cancer is an aggressive tumor owing to its ability to metastasize from stage II onward. Herein, lipid nanoparticles (LNPs) that encapsulate combination of small interfering RNAs (siRNAs), polo-like kinase-1...